Here are the S-1 registration statements from Lakewood-Amedex Biotherapeutics Inc. (LABT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow LABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LABT filings page.
Lakewood-Amedex Biotherapeutics Inc. (LABT) has filed a Form S-1 to register for resale up to 4,512,400 shares of common stock, all to be sold from time to time by a single selling stockholder upon conversion of its Series C Preferred Stock; the company states it will not receive any proceeds from these resales, though it will bear registration expenses.
These shares represent the additional common stock now issuable at the $1.00 per-share conversion floor that was not covered by an earlier S-1 that registered 937,500 shares already issued on conversion of 486,260 Series C Preferred shares. LABT previously raised $7.5 million gross ($6.8 million net) through the Series C financing and effected a one-for-ten reverse stock split on June 19, 2026. The company is a clinical-stage biotech developing its Bisphosphocin® antimicrobial platform, led by Nu-3 gel for infected diabetic foot ulcers, and reported no revenue and a $3.85 million net loss in 2025 with a going-concern explanatory paragraph in its audited financials.
Lakewood-Amedex Biotherapeutics Inc. has filed a Form S-1 covering the resale of up to 9,647,726 shares of common stock. This includes 9,375,000 shares issuable upon conversion of Series C Preferred Stock sold in a January 2026 private placement and 272,726 shares issued to RBW Capital Partners LLC as advisory compensation. The company will not receive proceeds from these resales, though it previously raised $7.5 million via the Series C financing and short-term notes.
Lakewood-Amedex is a clinical-stage biotechnology company developing Bisphosphocin antimicrobial candidates, led by Nu-3 gel for mildly infected diabetic foot ulcers, and early-stage programs for urinary tract and pulmonary infections. For 2025, the company reported no revenue, a net loss of $3.85 million, cash of $236,400, total assets of $481,598, liabilities of $2.45 million, and a stockholders’ deficit of $1.96 million, with its auditors expressing substantial doubt about its ability to continue as a going concern. It qualifies as an emerging growth and smaller reporting company, using scaled disclosure and extended accounting transition relief.